BIO Asia–Taiwan 2021 亞洲生技大會

BIO Asia–Taiwan 2021 亞洲生技大會


Claire Hughes Love

Session 1 – Plenary-Global Perspectives: A Brave New Era for Biotechnology

Date:21 July (Wednesday)
Time:  09:00 – 12:10 (GMT+8)

Claire Love

Principal and Partner in Deals Strategy for Pharma and Life Sciences
PricewaterhouseCoopers LLP (PwC)

Claire Love is the Principal and Partner in Deals Strategy for Pharma and Life Sciences at United States. Before join PwC, Claire has 15+ years of experience, primarily spent in healthcare strategy at the Boston Consulting Group.  Claire brings deep expertise in the biopharma and life science space across disease areas, geographies and functions.  In particular, Claire has led commercial due diligences across pharma and med tech assets as well as in service providers to them (eg, CRO, CDMO).  Over the last few years, she has been particularly focused in the cell and gene therapy space.
Claire has published in Harvard Business Review on "Your Strategy Needs a Strategy".  Claire earned her MBA from Harvard Business School with honors and her MPA from Harvard Kennedy School.  She earned her BA from Yale University in economics and international studies.  She also studied at Oxford.  Prior to her consulting career, she worked at Credit Suisse in equity research and structured credit products.
Select Project Experience:
Commercial due diligence assessments for private equity across pharma services, pharma tech and med devices with a particular focus on gene therapy related assets.
Growth strategy, due diligence, portfolio prioritization projects for biopharma clients in the genetic medicine, vaccine, immunology, oncology, rare disease, neuroscience, cardiovascular, dermatology, women’s health and diagnostic spaces; work included cross-functional teams across commercial, medical, development, research, and manufacturing.
Organizational transformation and integration efforts for top 5 commercial biopharma, including sales force, marketing, market access, and medical affairs model redesign and integration.

Speech title & Synopsis

COVID-19: 2021 PE Investment Opportunities